Antisoma follow-up data further supports AS1411's anticancer effects

By Angela McDaniels

Seattle, Nov. 16 - Antisoma plc said long-term follow-up data from the phase 1 trial of its aptamer anticancer drug AS1411 show that one of the three renal cancer patients is still in complete remission 16 months after treatment, one renal patient's disease remained stable for 9 months and another for 15 months.

The trial was conducted at the Brown Cancer Center at the University of Louisville and led by Donald Miller.

Ongoing scientific work on AS1411 by Antisoma has found that the drug kills a wide range of solid and blood cancer cells in culture, renal cancer lines amongst them, and that AS1411 inhibits lung tumor formation in a mouse model of metastatic cancer, the company said.

The update was presented Tuesday at the International Conference on Molecular Targets and

Cancer Therapeutics, a joint conference held by the American Association for Cancer Research, American National Cancer Institute and European Organization for Research and Treatment of Cancer in Philadelphia

Antisoma said the phase 1 trial of AS1411 has now reopened and is focusing on patients with renal and non-small cell lung cancers.

Based in London, Antisoma is a biopharmaceutical company that develops products for the treatment of cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.